Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Rating of “Hold” from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have received an average recommendation of “Hold” from the twelve research firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $5.2188.

Several equities analysts have recently commented on MRVI shares. Royal Bank Of Canada dropped their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Tuesday, August 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Maravai LifeSciences in a research note on Saturday, September 27th.

Hedge Funds Weigh In On Maravai LifeSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Callan Family Office LLC bought a new position in Maravai LifeSciences in the 2nd quarter valued at approximately $25,000. Ethic Inc. acquired a new position in Maravai LifeSciences in the 2nd quarter valued at approximately $26,000. McAdam LLC acquired a new position in Maravai LifeSciences in the 1st quarter valued at approximately $31,000. EntryPoint Capital LLC acquired a new position in Maravai LifeSciences in the 1st quarter valued at approximately $32,000. Finally, Prudential Financial Inc. acquired a new position in Maravai LifeSciences in the 2nd quarter valued at approximately $36,000. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

Shares of NASDAQ:MRVI opened at $3.19 on Monday. The firm has a 50 day moving average of $2.64 and a 200-day moving average of $2.37. The stock has a market capitalization of $814.60 million, a PE ratio of -2.35 and a beta of 0.33. The company has a current ratio of 5.16, a quick ratio of 4.49 and a debt-to-equity ratio of 0.68. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $8.53.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.